Fetal thalidomide syndrome (FTS) is a congenital syndrome that develops in a fetus as a result of a pregnant woman's exposure to thalidomide. Thalidomide, originally developed as an antiemetic, has become known for its teratogenic properties, causing a number of serious developmental abnormalities in newborns if the drug is used in the first trimester of pregnancy. The main manifestations of FTS include underdevelopment of the limbs (micromelia), abnormalities of the structure of the ears, eyes, and heart, as well as developmental abnormalities in other organs. These changes are a consequence of the effect of the substance on the processes of cellular migration and differentiation, which significantly complicates not only the physical but also the social development of children born with this syndrome.
History of the disease and interesting historical facts
Thalidomide was first introduced into medical practice in the late 1950s as an anxiolytic and antiemetic for pregnant women. However, its negative effects on the fetus only became apparent several years later. The first cases of abnormalities in newborns were reported in Germany, and the widespread use of the drug around the world soon led to thousands of cases of fetal thalidomide syndrome. More than 10,000 children were born with the effects of thalidomide, and many did not survive to adulthood. Importantly, the events surrounding thalidomide became the basis for the creation of new regulations in the field of drug control, which led to stricter standards for clinical trials and pharmaceutical safety.
Epidemiology
Statistics on fetal thalidomide syndrome vary by region and time period. At its peak in the 1960s, the number of people born with FTS was in the tens of thousands, but since the ban on thalidomide use, there has been no new increase in the incidence. According to the World Health Organization (WHO), only in countries with poor drug control may cases of FTS persist. The estimated worldwide incidence is 1 to 3 cases per 10,000 live births, but in those with a criminal record of prior thalidomide use, the rate may be significantly higher, especially in communities where the drug was used without control.
Genetic predisposition to this disease
Traditionally, FTS has been considered to have no clear genetic predisposition, since the cause of the syndrome is the exposure of the fetus to a chemical. However, studies show that certain genetic mutations can reduce the resistance of the fetus to teratogenic effects. In particular, the study of genes associated with drug metabolism (for example, genes encoding the CYP450 system) can provide additional information on the predisposition to FTS. Moreover, there is evidence that polymorphisms in genes responsible for the regulation of cell proliferation and differentiation can increase the risk of impaired normal development under the influence of thalidomide.
Risk factors for the development of this disease
Risk factors for the development of fetal thalidomide syndrome include:
- Use of thalidomide during pregnancy, especially in the first trimester.
- Certain medical conditions, such as nausea and vomiting, require medical intervention.
- Lack of awareness of the potential effects of thalidomide on pregnant women.
In addition, it should be taken into account that the socioeconomic status and level of medical education of mothers may also influence the frequency of use of this drug and, as a consequence, the prevalence of FTS.
Diagnosis of this disease
Diagnosis of fetal thalidomide syndrome usually begins with a clinical examination and assessment of developmental patterns. Key symptoms include:
- Anomalies in the structure of the limbs (micromelia).
- Underdevelopment of the auricle and other anomalies in the structure of the ear.
- Problems with the organs of vision.
- Heart defects.
- Pathologies of internal organs, including kidneys and intestines.
Laboratory testing may include genetic testing and teratogen testing, although most diagnoses are made based on imaging findings. Radiologic imaging, such as ultrasound, may help identify structural abnormalities early. The differential diagnosis may include a variety of genetic syndromes and abnormalities that require careful clinical evaluation.
Treatment
Treatment of fetal thalidomide syndrome is symptomatic and supportive in most cases. The focus is on:
- General treatment aimed at rehabilitation and assistance in mastering motor skills.
- Pharmacological treatment of concomitant diseases and conditions arising from anatomical anomalies.
- Surgical treatment that may be required to correct anatomical defects (eg, palliative surgery on the limbs).
Other approaches may include physical therapy and speech therapy, depending on the child's individual needs.
List of medications used to treat this disease
Pharmacological treatment for FTS varies and may include the following:
- Analgesics to reduce pain.
- Medicines for the correction of concomitant diseases.
- Vitamins and minerals to improve overall health.
However, it should be noted that there are no specific drugs directly aimed at correcting FTS.
Disease monitoring
Monitoring of patients with fetal thalidomide syndrome includes regular medical examinations aimed at assessing functional status and quality of life. The prognosis varies depending on the severity of the abnormalities, but early disability and the need for long-term support are the most common complications. The most important aspects of monitoring remain:
- Assessment of motor skills.
- Psychological support.
- Adaptation in the social and educational environment.
Age-related features of the disease
Fetal thalidomide syndrome manifests itself differently depending on the age group. In early childhood, motor development and communication problems are particularly important. Adolescents and young adults may experience social and psychological difficulties associated with physical anomalies, which may require interventions and support at all developmental levels.
Questions and Answers
- How do you know if your baby has fetal thalidomide syndrome? The main symptoms include abnormalities in the structure of the limbs, ears and heart. If you have these signs, you should consult a doctor.
- Could thalidomide affect the health of future generations? Since thalidomide does not cause genetic mutations, effects on offspring are not expected, but potential risks must be considered in the context of genetic predisposition.
- Are there any treatments for children with FTS? Yes, therapy includes rehabilitation approaches, physical therapy and specialist support aimed at improving quality of life and motor skills.
- What is the likelihood of having a child with FTS in a repeat pregnancy? Provided there is no exposure to thalidomide, the likelihood remains low, but awareness and avoidance of its use during pregnancy are important.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov notes that it is extremely important to ensure that women are informed about the potential risks associated with the use of thalidomide. If questions arise, it is necessary to contact a doctor who can provide detailed information about the potential consequences. He also recommends:
- Undergo regular medical check-ups and examinations during pregnancy.
- Discuss any medications you take during pregnancy with your doctor.
- Pay attention to symptoms that may indicate possible abnormalities in the fetus and seek medical attention if they are detected.
These measures will help reduce the risk of fetal thalidomide syndrome and other teratogenic effects on the developing fetus.
